Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 3 1

Status

Unknown 3Recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Nasopharyngeal Carcinoma 35Esophageal Squamous Cell Carcinoma 19Carcinoma, Non-Small-Cell Lung 19Carcinoma, Hepatocellular 18Squamous Cell Carcinoma of Head and Neck 15Triple Negative Breast Neoplasms 14Breast Neoplasms 12Uterine Cervical Neoplasms 11Colorectal Neoplasms 11Small Cell Lung Carcinoma 10Melanoma 10Carcinoma, Renal Cell 9Stomach Neoplasms 8Recurrence 8Head and Neck Neoplasms 7Rectal Neoplasms 5Neoplasm Metastasis 5Esophageal Neoplasms 5Carcinoma, Transitional Cell 5Advanced Solid Tumor 5Urinary Bladder Neoplasms 4Sarcoma 4Pancreatic Neoplasms 4Neoplasms 4Liver Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4Cholangiocarcinoma 4Solid Tumor 3Nasopharyngeal Neoplasms 3

Interventions

Gemcitabine 82Cisplatin 52Oxaliplatin 36lenvatinib 24durvalumab 22Capecitabine 22Fluorouracil 20Leucovorin 15tislelizumab 11pembrolizumab 10apatinib 10Radiotherapy 10Albumin-Bound Paclitaxel 10Radiofrequency Ablation 9Magnetic Resonance Spectroscopy 9Irinotecan 9Floxuridine 9Liver Transplantation 8Drug Therapy 8Cholangiopancreatography, Endoscopic Retrograde 8130-nm albumin-bound paclitaxel 8Taxes 7Platinum 7Photochemotherapy 7Panitumumab 7Biopsy 71,2-diaminocyclohexaneplatinum II citrate 7tremelimumab 6pemigatinib 6camrelizumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Cholangiocarcinoma × toripalimab × Clear all
NCT05342194 2025-04-23

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

Shanghai Junshi Bioscience Co., Ltd.

Phase 3 Recruiting
480 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT05215665 2024-12-11

GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma

Tianjin Medical University Cancer Institute and Hospital

Phase NA Unknown
146 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT04211168 2023-03-29

Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers

Peking Union Medical College Hospital

Phase 2 Unknown
44 enrolled
Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT05448183 2022-07-07

An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma

The First Affiliated Hospital of Zhengzhou University

Phase 2 Unknown
45 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡